Cargando…

M(2)-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway

The aim of the study was to investigate the effects of lactic acid on the phenotypic polarization and immune function of macrophages. The human monocyte/macrophage cell line, THP-1, was selected and treated with lactic acid. Immunofluorescence staining, laser confocal microscopy, reverse-transcripti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shan, Tao, Chen, Shuo, Chen, Xi, Wu, Tao, Yang, Yi, Li, Shunle, Ma, Jiancang, Zhao, Jing, Lin, Wanrun, Li, Wei, Cui, Xijuan, Kang, Ya'an
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551099/ https://www.ncbi.nlm.nih.gov/pubmed/33000216 http://dx.doi.org/10.3892/or.2020.7767

Ejemplares similares

MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior
por: Chen, Shuo, et al.
Publicado: (2018)

Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism
por: Shan, Tao, et al.
Publicado: (2017)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells
por: Chen, Shuo, et al.
Publicado: (2018)

Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells
por: Chen, Shuo, et al.
Publicado: (2022)

Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1(+) TAM expansion
por: Li, Bin, et al.
Publicado: (2019)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Novel regulatory program for norepinephrine-induced epithelial–mesenchymal transition in gastric adenocarcinoma cell lines
por: Shan, Tao, et al.
Publicado: (2014)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study
por: Wilson, Julie K., et al.
Publicado: (2018)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs
por: Gok Yavuz, Betul, et al.
Publicado: (2019)

PD‐L1/p‐STAT3 promotes the progression of NSCLC cells by regulating TAM polarization
por: Zhang, Rui, et al.
Publicado: (2022)

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Huang, Zi-Lu, et al.
Publicado: (2019)

Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
por: Zhang, Wei, et al.
Publicado: (2023)

PD-1-stimulated T cell subsets are transcriptionally and functionally distinct
por: Lerrer, Shalom, et al.
Publicado: (2021)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective
por: Li, HaiXia, et al.
Publicado: (2021)

PD-L1 mediates triple-negative breast cancer evolution via the regulation of TAM/M2 polarization
por: Meng, Ziqi, et al.
Publicado: (2022)

Imbalance of Circulating Monocyte Subsets and PD-1 Dysregulation in Q Fever Endocarditis: The Role of IL-10 in PD-1 Modulation
por: Ka, Mignane B., et al.
Publicado: (2014)

A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease
por: Wu, Ching-Tse, et al.
Publicado: (2022)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer
por: Sumitomo, Ryota, et al.
Publicado: (2022)

Features of Memory-Like and PD-1(+) Human NK Cell Subsets
por: Della Chiesa, Mariella, et al.
Publicado: (2016)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Efficient visible-light photocatalytic degradation system assisted by conventional Pd catalysis
por: Yu, Yanlong, et al.
Publicado: (2015)

Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)
por: Li, Yue, et al.
Publicado: (2021)

Analysis of Regulatory T Cell Subsets and Their Expression of Helios and PD-1 in Patients with Hashimoto Thyroiditis
por: Hu, Yifang, et al.
Publicado: (2019)

ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
por: Chen, Xiaozheng, et al.
Publicado: (2021)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Expression and significance of PD-1 and PD-L1 in patients with recurrent spontaneous abortion: A protocol for systematic review and meta-analysis
por: Li, Tao, et al.
Publicado: (2021)

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5qucv8oe6tbf7895e52i2p9nlt